Point taken

Idera's 3GA antisense DNA oligos co-opt the potency and specificity of siRNA

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) has identified an siRNA-like mechanism that may explain the unexpected potency and pinpoint specificity of its third-generation antisense (3GA) DNA technology, which allows for selective silencing of disease-causing alleles.

Antisense oligonucleotides (ASOs) and short interfering RNAs (siRNAs) both silence genes by inducing degradation of target RNA, but operate via different mechanisms. Each has its pros and cons.

ASOs are chemically

Read the full 638 word article

How to gain access

Continue reading with a
two-week free trial.